Profound Medical Corp.
6.13-0.07 (-1.13%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · PROF · USD
Key Stats
Market Cap
186.58MP/E (TTM)
-Basic EPS (TTM)
-1.45Dividend Yield
0%Recent Filings
8-K
Record Q3 revenue surge
Profound Medical reported preliminary unaudited Q3 2025 revenues of $5.2 million to $5.3 million, up 84% to 87% from $2.8 million last year, fueled by TULSA-PRO installed base growth to 67 systems from 60. Gross margin hit 72%, beating prior year's 64%, thanks to higher utilization. The company eyes at least 75 systems by year-end. Actuals may vary amid regulatory and market risks.
10-Q
Q2 FY2025 results
Profound Medical's Q2 revenue dipped 1% y/y to $2.2M, yet recurring non-capital sales climbed 7% to $1.6M, lifting gross margin to 73% from 64% on manufacturing efficiencies and higher-margin capital buyouts. Operating loss widened to $13.8M from $7.8M, driven by 45% higher R&D on CAPTAIN trial enrollment and 84% steeper SG&A from sales force expansion and commissions; net loss hit $15.7M, or $0.52 per share, versus $6.9M last year, with EPS aligning to 30M diluted shares amid anti-dilution from options and RSUs. Cash burned $22M in operations, leaving $35.2M at quarter-end, while $4.5M long-term debt under the CIBC revolver (6.25% floor, due 2027) carries covenants projecting a breach by year-end without waiver. No M&A or non-GAAP metrics disclosed in the 10-Q. Regulatory hurdles in expanding TULSA-PRO approvals could slow adoption.
8-K
Q2 revenue flat, margins up
Profound Medical reported Q2 2025 revenue of $2.2 million, flat year-over-year, with recurring non-capital revenue at $1.6 million and capital sales at $650,000, but gross margins expanded to 73% from 64% thanks to manufacturing efficiencies. Procedure volumes rose 10% sequentially, while the sales pipeline swelled to 80 TULSA-PRO systems; yet operating expenses jumped to $15.4 million, driving a $15.7 million net loss. Delays cost a few sales, but the company eyes 70-75% full-year revenue growth. Cash burn accelerates.
8-K
Wheeler joins as TULSA ambassador
Profound Medical named former NFL safety Leonard Wheeler as Global Ambassador for its TULSA-PRO system on June 4, 2025, via a consulting agreement. Wheeler, a recent TULSA patient who beat prostate cancer while preserving quality of life, will build in-person and digital communities to educate men and boost awareness. This partnership launches a 2025 campaign across digital media, social platforms, and podcasting to drive adoption. Yet risks like regulatory hurdles could temper outcomes.
8-K
Shareholders approve directors, auditors
Profound Medical Corp. shareholders at the May 14, 2025 annual meeting elected six directors—Arun Menawat, Brian Ellacott, Cynthia Lavoie, Murielle Lortie, Arthur Rosenthal, and Kris Shah—with strong support ranging from 92.4% to 97.0%. They ratified PricewaterhouseCoopers LLP as auditors, garnering 99.5% approval. Yet the unallocated share options resolution passed narrowly at 68.3%. This bolsters governance continuity while signaling scrutiny on equity incentives.
IPO
Employees
Sector
Industry
BDMD
Baird Medical Investment Holdin
1.44+0.02
BSX
Boston Scientific Corporation
100.30-0.67
EMED
Electromedical Technologies, In
0.00+0.00
ICCM
IceCure Medical Ltd.
0.75-0.02
PDEX
Pro-Dex, Inc.
30.71+2.00
PFSA
Profusa, Inc.
0.29-0.00
PRCT
PROCEPT BioRobotics Corporation
35.93-1.02
SNWV
SANUWAVE Health, Inc.
30.44-0.60
VERO
Venus Concept Inc.
2.18+0.05
ZOMDF
Zomedica Corp.
0.07+0.00